Compare · AZN vs KALV
AZN vs KALV
Side-by-side comparison of AstraZeneca PLC (AZN) and KalVista Pharmaceuticals Inc. (KALV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and KALV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $550.35B, about 383.7x KALV ($1.43B).
- Over the past year, AZN is down 6.3% and KALV is up 101.4% - KALV leads by 107.7 points.
- AZN has been more active in the news (24 items in the past 4 weeks vs 17 for KALV).
- AZN has more recent analyst coverage (25 ratings vs 8 for KALV).
- Company
- AstraZeneca PLC
- KalVista Pharmaceuticals Inc.
- Price
- $176.33-0.62%
- $26.95-0.02%
- Market cap
- $550.35B
- $1.43B
- 1M return
- -3.87%
- +0.99%
- 1Y return
- -6.35%
- +101.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2015
- News (4w)
- 24
- 17
- Recent ratings
- 25
- 8
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.
Latest AZN
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest KALV
- Amendment: SEC Form SC 14D9/A filed by KalVista Pharmaceuticals Inc.
- CHIEF DEVELOPMENT OFFICER Yea Christopher exercised 33,800 shares at a strike of $7.07 and sold $905,225 worth of shares (33,800 units at $26.78) (SEC Form 4)
- KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
- Chief Commercial Officer Sweeny Nicole sold $39,872 worth of shares (1,489 units at $26.78) and converted options into 5,000 shares, increasing direct ownership by 6% to 59,291 units (SEC Form 4) to cover withholding tax
- CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 5,000 shares and sold $59,955 worth of shares (2,239 units at $26.78), increasing direct ownership by 2% to 150,260 units (SEC Form 4) to satisfy tax liability
- CHIEF DEVELOPMENT OFFICER Yea Christopher converted options into 3,125 shares and sold $52,645 worth of shares (1,966 units at $26.78), increasing direct ownership by 0.51% to 229,918 units (SEC Form 4) (tax liability)
- CHIEF EXECUTIVE OFFICER Palleiko Benjamin L converted options into 23,250 shares and sold $292,646 worth of shares (10,926 units at $26.78), increasing direct ownership by 3% to 479,989 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Sweeny Nicole converted options into 6,250 shares and sold $49,846 worth of shares (1,861 units at $26.78), increasing direct ownership by 9% to 55,780 units (SEC Form 4) to satisfy tax liability
- CHIEF DEVELOPMENT OFFICER Yea Christopher sold $63,158 worth of shares (2,358 units at $26.78) and converted options into 3,750 shares, increasing direct ownership by 0.61% to 228,759 units (SEC Form 4) to satisfy withholding obligation
- CHIEF MEDICAL OFFICER Audhya Paul K. converted options into 6,250 shares and sold $71,916 worth of shares (2,685 units at $26.78), increasing direct ownership by 2% to 147,499 units (SEC Form 4) to cover withholding tax